

## Supplementary Information

### **Controlled production of the elusive metastable form II of paracetamol: a fully scalable multicomponent templating approach in a cooling environment**

*Lauren R. Agnew<sup>a,b</sup>, Dyanne L. Cruickshank<sup>a,c</sup>, Thomas McGlone<sup>d</sup> and Chick C. Wilson<sup>a,b,\*</sup>*

<sup>a</sup> Department of Chemistry, University of Bath, Bath, BA2 7AY, U.K.; <sup>b</sup> EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation (CMAC), University of Bath, Bath, BA2 7AY, U.K.; <sup>c</sup> Department of Chemistry, University of Cape Town, Cape Town, Rondebosh 7701, South Africa; <sup>d</sup> EPSRC Centre for Innovative Manufacturing in Continuous Manufacturing and Crystallisation (CMAC) c/o Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Technology Innovation Centre, 99 George Street, Glasgow, G1 1RD, U.K.


#### **Experimental**

PC, 4-BrBA, 4-CIBA and 4-FBA were all purchased from Sigma Aldrich Chemie GmbH (Steinheim, Germany). Metacetamol (3'-hydroxyacetanilide) was purchased from TCI Ltd. All were used without further purification. Laboratory grade solvents purchased from Sigma Aldrich were used for all crystallisations.


**Powder X-ray diffraction (PXRD).** PXRD patterns were collected in flat plate mode on a Bruker D8 Advance equipped with monochromated Cu-K $\alpha$  radiation ( $\lambda = 1.54056 \text{ \AA}$ ) in reflection geometry at 298 K.

**Differential Scanning Calorimetry (DSC).** Differential scanning calorimetry studies were carried out using a Thermal Advantage Q20 DSC from TA Instruments, equipped with Thermal Advantage Cooling System 90 and operated with a dry nitrogen purge gas at a flow rate of  $18 \text{ cm}^3 \text{ min}^{-1}$ . The samples were placed in sealed Tzero aluminium pans and a heating rate of  $5 \text{ K min}^{-1}$  was used. Data were collected using the software Advantage for Qseries (Ver. 5.40 software © 2001-2011 TA Instruments-Waters LLC).


**Solubility Measurements.** Solubility measurements were carried out in a 60:40 Water:IPA solvent system using a Crystal16 parallel crystalliser from Technobis using turbidity probes on 1 mL samples. Vials were subjected to a heat/cool cycle from  $20 \text{ }^\circ\text{C}$  to  $75 \text{ }^\circ\text{C}$  and back again using a heating rate of  $0.5 \text{ }^\circ\text{C min}^{-1}$  and bottom stirring at 800 rpm using standard magnetic stirrer bars. Data were analysed using CrystalClear software version 1.0.1.614 supplied by Technobis.



**Figure S1.** Solubility curves of the templating co-formers (a) 4-bromobenzoic acid, (b) 4-chlorobenzoic acid, (c) 4-fluorobenzoic acid



**Figure S2.** PXRD pattern showing the match of the bulk sample to that calculated from single crystal data



**Figure S3.** DSC pattern showing a phase transition between 130-140  $^{\circ}\text{C}$




Figure S4: PXRD patterns showing the stability of the form II samples produced over a period of 9 months